• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Emergent BioSolutions

    Almac Group

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Baxter BioPharma Solutions

    Almac Group

    Alcami

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Innovate UK Grant Supports Viral Vector Manufacturing

    Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment

    Innovate UK Grant Supports Viral Vector Manufacturing
    Related CONTENT
    • Catalent Acquires Delphi Genetics
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    • iosBio Inks Exclusive Vax Platform Pact for COVID-19
    • Passage Bio Invests in Gene Therapy Manufacturing R&D Site
    Betsy Louda, Associate Editor04.10.18
    Cobra Biologics is an international contract development and manufacturing organization (CDMO) that provides biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The CDMO has three GMP approved facilities in Sweden and the UK, from which its offers a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. Recently, the company was awarded £2.6 million ($3.4 million) capital infrastructure investment by Innovate UK. The award was given under Innovate UK’s Industrial Strategy boost for UK medicines with £70 million of funding to help develop new treatments. The investment will go towards a £5 million development project, which feeds into a £15 million company expansion announced by Cobra in 2017. The expansion will be to advance capabilities for clinical and commercial production of viral vectors and DNA, vital for gene therapy and immune-oncology programs. The extended capacity and capability will allow Cobra increased process development, analytics and GMP manufacturing, and provides the necessary infrastructure to offer commercial in-market supply of viral vector and DNA products to Advanced Therapy Medicinal Product (ATMP) developers. The expansion will double the footprint of Cobra’s UK site and create 25-35 additional jobs. Contract Pharma recently spoke with Dr. Daniel C. Smith, chief science officer, Cobra Biologics, about the recent investment and the company’s plans. —Betsy Louda


    Contract Pharma: Cobra is in the middle of a large expansion. Where will Innovate UK’s grant be used within that project?

    Daniel Smith, CSO Cobra Biologics
    Daniel Smith: The Innovate UK grant will be used to support a larger investment being made by Cobra to expand its offering segregating clinical development and production from commercial manufacture and analytics. Specifically, the grant has been awarded to support investment in research, development and manufacturing capital infrastructure and equipment.

    The planned expansion at Cobra will increase GMP manufacturing capacity to 600 square meters, and GMP analytical capacity by 80%, doubling the overall site footprint shared across two buildings.

    The grant (£2.576m) will de-risk and unlock further investment as part of a larger project at Cobra. Specifically, it will help fund the capital refurbishment, capital equipment purchase, and set-up costs for the new and expanded capacity and capability.

    The project will involve three phases:
    1. Remodeling the current facility to provide additional development and QC laboratories, equipment, allowing segregation, appropriate work and personnel flows;
    2. Re-siting of the current GMP warehouse and offices to a new building, including procurement, the set-up of storage and warehouse equipment along with the integration of electronic inventory, fully automated material traceability systems—qualified and validated for 21 CFR Part 11 compliance—along with the relocation of non-laboratory based Cobra employees to the new building; and
    3. Remodeling the existing building to add two new GMP clean suites specific for viral vector manufacture, installation of HVAC systems and dedicated process equipment for commercial vector batches.
    Grant funding will allow all three phases to initiate and run in parallel delivering an expanded commercial service offering within 12 months, ensuring customer deadlines are met and existing revenue generating activities at Cobra progress in line with operational targets.

    CP: What will Cobra’s expansion ultimately be able to offer to counterparts within the Pharma industry?
    DS:
    The expanded capacity and capability will allow increased process development, analytical and GMP manufacturing; importantly providing the necessary infrastructure to offer commercial in-market supply of DNA and viral vector products to ATMP developers.

    This will provide Cobra, and the UK, with a unique opportunity for the production of gene therapy and immune oncology products.

    In addition, the grant will allow Cobra to invest in state-of-the-art technology, providing straight-forward implementation for faster viral vector process development and linear scalability from R&D to manufacturing. Expansion will synergize with existing expertise and track record in clinical development and production, providing customers with a runway from development via clinical to commercial production of viral vectors.

    CP: Beyond added capacity, will this investment also be adding jobs to the company? If so, what type of roles will be created?
    DS:
    The expansion will create 25-35 jobs and it is expected that the roles will cover a wide range of disciplines, including analytics, process development, manufacturing, quality, engineering and technical support services.

    CP: What qualities does Cobra Biologics have in common with other organizations who were selected for this award?
    DS:
    Cobra was the only CDMO selected for the award, the other recipients have their own internal pipeline of viral vector products. Cobra has a balance of traditional development and manufacturing capabilities linked to innovative R&D activities that helps maintain a strong market position in relation to process understanding, manufacturing technology, end-to-end supply chain knowledge for viral vectors and other innovative advanced biological medicines.

    The target market is the outsourced development and manufacturing of viral vectors for ATMP gene therapy treatments and CAR-T based cell immunotherapies. The global market (>95% of target customers outside of the UK) consists of predominately biopharma drug developers and large pharma companies who lack suitable GMP manufacturing capability or capacity. As such, Cobra has been identified as being one of five companies globally that has the capability for larger scale GMP production of both plasmid DNA and viral vectors, putting Cobra in a strong competitive position that clearly differentiates us from our competitors.

    Currently, the business model to procure plasmid DNA and perform clinical production independently of commercial viral vector manufacture, generates overly complex supply chains. For example, in the UK academic centers support vector manufacture for early phase trials, but are not seen by industry or regulators as viable options for commercial supply. With Cobra being able to offer a complete development to commercial service for both viral vectors and plasmid DNA will provide existing and new customers a comprehensive service under one roof for gene therapy and immune oncology product manufacture with a simplified outsourcing supply chain.

    CP: In such a competitive CDMO and overall pharmaceutical landscape, what does it mean to you to be chosen to receive the grant?
    DS:
    Strategically, expansion of capacity and capability will allow Cobra to offer customers in-market commercial viral vector manufacturing, in addition to the established clinical IMP viral vector production services. Commercially, this would further strengthen and grow Cobra’s position in the market, providing the UK and global customers a comprehensive service for gene therapy production and a unique viral vector/DNA CDMO capacity in the UK.

    Furthermore, the expansion will allow Cobra to advance viral vector research and development and manufacturing by offering commercial in-market viral vector manufacturing capacity, alongside existing development and analytical services, across both lentiviral and AAV vectors including the requisite plasmid DNA; these vector types represent over 50% of products currently in clinical trials (Roots Anal.2016; Alliance for Regenerative Medicine Release, Q3 2016 Data Report).

    Overall the grant will ensure that Cobra can anchor manufacturing of these potentially curative gene therapies in the UK and secure its position as a global hub for advanced therapies, helping to realize the ambition of the Advanced Therapies Manufacturing Action Plan and the UK Life Science Industrial Strategy.

    The project will allow alignment of new commercial manufacturing with existing process development and clinical production such that the value proposition to customers working with Cobra is strengthened as a complete end to end contract manufacturing service.

    Investment in R&D activities, both internally and via external collaborations will increase from the current 5-7% of revenue up to 10-12% of revenue by 2020 as a consequence of increased capability and capacity, and as the market demands faster, lower costs manufacturing plat-forms Financial modelling (2018-2020; conservative estimate; 65% facility utilization; Cobra in house data) has predicted that the expanded viral vector capacity and associated capability will result in a 75% increase in revenues for Cobra from £8.6m in 2017 to £15.0m in 2020 (EBITDA up from 30% to 50%), directly attributable to late clinical and commercial viral vector manufacturing.

    CP: What’s the significance of the additional award with Symbiosis, and what its use entails within that partnership
    DS:
    Establishing commercial manufacturing capacity and capability at Cobra will directly align with a recently initiated Innovate UK funded collaborative project with Symbiosis Pharmaceutical Services (Stirling, UK), a specialist CDMO offering niche sterile GMP Drug Product manufacturing services.

    The joint project between Cobra and Symbiosis will simplify and improve the contiguous supply chain for viral vector manufacture in the UK by reducing project transfer complexity, transition time and the inherent drug development risk for the drugs being developed by our existing, shared client, for example. The high value, time and resource invested in drug synthesis, and with viral vector manufacture in particular means that every effort to de-risk the development pathway and to foster the successful development of these niche drugs is crucial. Commercial expansion at Cobra coupled to increased alignment of DS/DP manufacture will provide significant benefit to Cobra and Symbiosis and the UK industry, however it will be our customers and ultimately patients who are eagerly awaiting these revolutionary drug therapies who will bene-fit the most from a time-optimized drug development supply chain for viral vector drugs here in the UK, specifically fueled by the joint Cobra/Symbiosis £1.9m ($2.5m) Innovate UK grant from the UK Government. 
    Related Searches
    • contract pharma
    • supply chain
    • Pharma
    • Process Development
    Suggested For You
    Catalent Acquires Delphi Genetics Catalent Acquires Delphi Genetics
    Thermo Fisher Buys Novasep Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    iosBio Inks Exclusive Vax Platform Pact for COVID-19 iosBio Inks Exclusive Vax Platform Pact for COVID-19
    Passage Bio Invests in Gene Therapy Manufacturing R&D Site Passage Bio Invests in Gene Therapy Manufacturing R&D Site
    CHA Biotech Launches Global CDMO Biz CHA Biotech Launches Global CDMO Biz
    HALIX, AstraZeneca Ink Commercial COVID-19 Vax Mfg. Pact HALIX, AstraZeneca Ink Commercial COVID-19 Vax Mfg. Pact
    Symbiosis Symbiosis
    Alcami Alcami
    Vibalogics Establishes U.S. Presence Vibalogics Establishes U.S. Presence
    CEVEC, Roche Ink ELEVECTA Technology License Agreement CEVEC, Roche Ink ELEVECTA Technology License Agreement
    Sensorion and Novasep Sign Agreement Sensorion and Novasep Sign Agreement
    Vigene Biosciences Appoints COO Vigene Biosciences Appoints COO
    MilliporeSigma Launches VirusExpress Platform MilliporeSigma Launches VirusExpress Platform
    Softweb Solutions Softweb Solutions

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines and Return-To-Normalcy

      Vaccines and Return-To-Normalcy

      Planning for a future in which COVID-19 won’t simply ‘disappear.’
      Ben Locwin, Contributing Editor 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20


    • Biologics, Proteins, Vaccines
      Outsourcing in China: How far can it go?

      Outsourcing in China: How far can it go?

      China’s biopharmaceutical services market is on pace to top $1 billion by 2021
      Vicky Qing Xia, BioPlan Associates 07.15.19

    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19

    • Biologics, Proteins, Vaccines | Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17


    • Biologics, Proteins, Vaccines
      India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Trends in New Technologies & Budgets

      Trends in New Technologies & Budgets

      Budget increases in biopharmaceutical industry indicate future growth
      Eric S. Langer, BioPlan Associates 06.06.17


    • Biologics, Proteins, Vaccines

      Biomanufacturing Trends and Outlook 2017: Where Is It All Going?

      A look at the technological advances permeating (bio)pharma manufacturing
      Ben Locwin, Contributing Editor 04.20.17

    • Biologics, Proteins, Vaccines
      CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges

      CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

      Technically trained staff needed to run complex manufacturing platforms, automation
      Eric S. Langer, BioPlan Associates 03.07.17

    • Biologics, Proteins, Vaccines

      Year-End Trends in Biopharma Contract Manufacturing

      Budgets are flattening, but some CMOs are well positioned for growth
      Eric S. Langer, BioPlan Associates 11.09.16


    • Biologics, Proteins, Vaccines

      Economics of In-House Buffer Preparation

      Evaluating the cost effectiveness of keeping basic ops in-house
      Eric S. Langer, BioPlan Associates 09.08.16

    • Biologics, Proteins, Vaccines | cGMP Manufacture | GMPs/GCPs | Preclinical Outsourcing | Process Development | Risk Management

      Getting to Yes

      The critical attributes CMOs need to demonstrate to win business
      Eric S. Langer, BioPlan Associates 07.14.15

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login